Durect Corp (FRA:DC8A)
€ 0.785 -0.015 (-1.88%) Market Cap: 25.87 Mil Enterprise Value: 29.05 Mil PE Ratio: 0 PB Ratio: 22.56 GF Score: 60/100

DURECT Corp at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 02:00PM GMT
Release Date Price: €3.74 (-2.60%)
Ed Arce
H. C. Wainwright & Co., LLC - Analyst

Great. Welcome, everyone. And our next presenting company is DURECT. I'm very pleased to have with us members of the senior management team. To my right is CEO, Jim Brown; and to my left is CFO, Tim Papp. Jim, Tim, thank you so much for joining us.

Tim Papp
DURECT Corporation - CFO

Thank you, Ed.

Jim Brown
DURECT Corporation - President & CEO

Thanks, Ed. It's great to see you.

Ed Arce
H. C. Wainwright & Co., LLC - Analyst

Yeah. So I wanted to start by just asking if you could provide a brief overview of the company and the current status of both your marketed and development programs.

Jim Brown
DURECT Corporation - President & CEO

Sure. Now, we -- as a company, we are focused on developing products that regulate the epigenome. And we have a history of once upon a time, we started as a company and especially the pharma space with drug delivery.

So we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot